Skip to main content
ACHIEVE LIFE SCIENCES, INC. logo

ACHIEVE LIFE SCIENCES, INC. — Investor Relations & Filings

Ticker · ACHV ISIN · US0044685008 LEI · 549300V82ZKZDTAU0A46 US Manufacturing
Open in API
Filings indexed 1,013 across all filing types
Latest filing 2010-02-25 Regulatory Filings
Country US United States of America
Listing US ACHV

About ACHIEVE LIFE SCIENCES, INC.

https://achievelifesciences.com/

Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company dedicated to addressing the global nicotine dependence epidemic. The company's primary focus is the development and commercialization of its lead product candidate, cytisinicline, for smoking cessation. Following the successful completion of two Phase 3 studies, the company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), which has been accepted for review. If approved, cytisinicline has the potential to become the first new FDA-approved treatment option for nicotine dependence in the United States in nearly two decades.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filing with the SEC, dated February 25, 2010. It includes a press release as an exhibit regarding the European Medicines Agency's agreement with the company's development plan. The text explicitly states that the information is a press release and is not deemed filed for certain regulatory purposes. The document length is 3031 characters, which is relatively short and primarily serves as an announcement of a press release rather than containing detailed financial data or comprehensive report content. There is no financial statement or detailed analysis present. Therefore, this document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2010-02-25 English
SC 13G/A
Major Shareholding Notification
2010-02-16 English
FEBRUARY 16, 2010
Major Shareholding Notification
2010-02-16 English
SC 13G/A
Major Shareholding Notification
2010-02-12 English
FORM 4 SUBMISSION
Director's Dealing
2010-01-29 English
Regulatory Filings 2010
Regulatory Filings Classification · 95% confidence The document is a letter from OncoGenex Pharmaceuticals to the SEC responding to verbal comments from the SEC staff regarding the company's Form 10-K for the fiscal year ended December 31, 2008. The letter discusses specific notes to the consolidated financial statements and planned modifications to disclosures in the upcoming 10-K filing for the fiscal year ended December 31, 2009. It is correspondence related to regulatory review and not the actual 10-K report itself. The document is relatively short (4635 characters) and serves as a response to SEC comments rather than containing full financial statements or substantive financial data. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for such correspondence and attestation documents.
2010-01-28 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.